| Diffuse Large B-Cell Lymphoma
Columvi vs Xpovio
Side-by-side clinical, coverage, and cost comparison for diffuse large b-cell lymphoma.Deep comparison between: Columvi vs Xpovio with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsXpovio has a higher rate of injection site reactions vs Columvi based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Xpovio but not Columvi, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Columvi
Xpovio
At A Glance
IV infusion
Every 3 weeks
CD20xCD3 bispecific T-cell engager
Oral
Once or twice weekly
XPO1 inhibitor
Indications
- Diffuse Large B-Cell Lymphoma
- Multiple Myeloma
- Diffuse Large B-Cell Lymphoma
Dosing
Diffuse Large B-Cell Lymphoma Pretreat with obinutuzumab 1,000 mg IV on Cycle 1 Day 1; then administer COLUMVI IV: 2.5 mg step-up dose on Cycle 1 Day 8, 10 mg step-up dose on Cycle 1 Day 15, then 30 mg on Day 1 of Cycles 2-12 (21-day cycles; maximum 12 cycles or until disease progression or unacceptable toxicity).
Multiple Myeloma (with Bortezomib and Dexamethasone) 100 mg orally once weekly on Day 1 of each week in combination with bortezomib 1.3 mg/m2 SC once weekly and dexamethasone 20 mg orally twice weekly on Days 1 and 2.
Multiple Myeloma (with Dexamethasone) 80 mg orally on Days 1 and 3 of each week in combination with dexamethasone 20 mg orally on Days 1 and 3 of each week.
Diffuse Large B-Cell Lymphoma 60 mg orally on Days 1 and 3 of each week until disease progression or unacceptable toxicity.
Contraindications
—
—
Adverse Reactions
Most common (>=20%) Cytokine release syndrome, musculoskeletal pain, rash, fatigue
Serious Cytokine release syndrome, COVID-19 infection, sepsis, tumor flare
Most common (>=20%) Fatigue, nausea, thrombocytopenia, decreased appetite, diarrhea, vomiting, weight decreased, anemia, peripheral neuropathy, upper respiratory tract infection, hyponatremia, cataract
Serious Thrombocytopenia, neutropenia, gastrointestinal toxicity (nausea, vomiting, diarrhea, weight loss), hyponatremia, serious infection (including pneumonia and sepsis), neurological toxicity, cataract
Pharmacology
Glofitamab-gxbm is a bispecific CD20-directed CD3 T-cell engager that binds CD20 on B cells and CD3 on T cells, causing T-cell activation and proliferation, cytokine secretion, and lysis of CD20-expressing B cells.
Selinexor reversibly inhibits exportin 1 (XPO1), blocking nuclear export of tumor suppressor proteins and oncogenic mRNAs, causing nuclear accumulation of tumor suppressors, downregulation of oncoproteins such as c-myc and cyclin D1, cell cycle arrest, and apoptosis of cancer cells.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Columvi
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (0/12) · Qty limit (0/12)
Xpovio
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (0/12) · Qty limit (11/12)
UnitedHealthcare
Columvi
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Xpovio
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (0/8) · Qty limit (2/8)
Humana
Columvi
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (0/3)
Xpovio
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
$0
Genentech Patient FoundationCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
$5/momo
Xpovio Co-Pay CardCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
ColumviView full Columvi profile
XpovioView full Xpovio profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.